Physician

Katherine Westin Kwon, M.D.

According to 2025 Medicare claims, Katherine Kwon, M.D. (NPI: 1891907770) practices nephrology in the Niles, MI market, with the plurality of this provider's patient population coming from Berrien, MI. This provider's primary affiliated billing organization is LAKE MICHIGAN NEPHROLOGY, L.L.C (NPI: 1821201500; TIN: 383572004) and primary practice location at 49085-8511.

Kwon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 211 traditional Medicare patients, billed 767 HCPCS/CPT codes, and received $84,004 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 1,845 prescription claims across 310 beneficiaries totaling $757,508 in drug costs, led by Jardiance (Empagliflozin). DME data shows 11 claims. Open Payments data shows 56 records totaling $77,170. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $445,896 to $757,508. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	536	1,720	$184,365
2016	460	1,556	$163,216
2017	513	1,741	$169,238
2018	532	1,899	$181,740
2019	662	2,261	$235,770
2020	618	2,252	$240,174
2021	534	1,730	$200,974
2022	421	1,382	$159,698
2023	346	1,056	$137,645
2024	211	767	$84,004

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	269	1,984	$445,896
2016	268	2,048	$554,459
2017	276	1,904	$544,526
2018	262	1,864	$275,116
2019	301	1,974	$190,102
2020	341	2,311	$218,173
2021	315	1,976	$250,814
2022	343	2,046	$522,984
2023	384	2,586	$687,139
2024	310	1,845	$757,508

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	26	$454
2019	N/R	65	$3,372
2020	N/R	81	$5,762
2021	N/R	43	$2,229
2022	N/R	39	$957
2023	N/R	39	$4,045
2024	N/R	11	$138

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	60	135	$300
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	27	33	$244
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	99	216	$88
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	45	89	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	99	206	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	277	15,467	$288,701
Farxiga	Dapagliflozin Propanediol	190	11,674	$213,321
Kerendia	Finerenone	58	3,580	$74,157
Veltassa	Patiromer Calcium Sorbitex	46	1,872	$58,086
Lokelma	Sodium Zirconium Cyclosilicate	35	1,159	$27,591

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	11	$138

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	56	$77,170	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Katherine Westin Kwon, M.D.?

Tedicare shows public-source Medicare data for Katherine Westin Kwon, M.D. (NPI 1891907770), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Katherine Westin Kwon, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Katherine Westin Kwon, M.D.?

Katherine Westin Kwon, M.D. is linked to LAKE MICHIGAN NEPHROLOGY, L.L.C (billing NPI 1821201500) in the available physician profile data.

Does Katherine Westin Kwon, M.D. have Open Payments data?

Katherine Westin Kwon, M.D. has 56 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.